Holen Sie sich die Stockscreener-App
25.04
0.93%
0.23
Handel nachbörslich:
25.04
Schlusskurs vom Vortag:
$24.81
Offen:
$24.87
24-Stunden-Volumen:
764.84K
Relative Volume:
1.08
Marktkapitalisierung:
$1.13B
Einnahmen:
$681.75M
Nettoeinkommen (Verlust:
$70.47M
KGV:
17.27
EPS:
1.45
Netto-Cashflow:
$173.19M
1W Leistung:
+11.79%
1M Leistung:
+9.34%
6M Leistung:
-5.62%
1J Leistung:
+101.94%
1-Tages-Spanne:
$24.77
$25.26
1-Wochen-Bereich:
$22.38
$25.50
52-Wochen-Spanne:
$12.14
$27.98
Pacira Biosciences Inc Stock (PCRX) Company Profile
Firmenname
Pacira Biosciences Inc
Sektor
Telefon
650-242-8052
Adresse
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
Vergleichen Sie PCRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
25.04 | 1.13B | 681.75M | 70.47M | 173.19M | 1.45 |
|
ZTS
Zoetis Inc
|
152.44 | 66.04B | 9.39B | 2.61B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.77 | 45.57B | 29.98B | 958.27M | 5.31B | 0.2964 |
|
HLN
Haleon Plc Adr
|
9.69 | 42.50B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.21 | 18.84B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
309.72 | 13.59B | 2.99B | 1.21B | 1.13B | 25.06 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-25 | Hochstufung | Truist | Hold → Buy |
| 2025-01-30 | Hochstufung | Truist | Sell → Hold |
| 2024-08-13 | Herabstufung | Truist | Buy → Sell |
| 2024-08-12 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2024-08-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-08-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-08-12 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2024-07-03 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-03-07 | Fortgesetzt | JP Morgan | Overweight |
| 2023-12-20 | Eingeleitet | Raymond James | Outperform |
| 2023-08-03 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-01-31 | Fortgesetzt | Wedbush | Outperform |
| 2022-10-21 | Fortgesetzt | Jefferies | Buy |
| 2022-01-03 | Fortgesetzt | JP Morgan | Overweight |
| 2021-07-26 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-04-21 | Fortgesetzt | JP Morgan | Neutral |
| 2021-04-09 | Eingeleitet | Berenberg | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2021-02-11 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2021-01-21 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-09-21 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2020-07-06 | Bestätigt | Needham | Buy |
| 2020-05-27 | Eingeleitet | Guggenheim | Neutral |
| 2020-04-07 | Eingeleitet | Northland Capital | Outperform |
| 2020-03-20 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-02-24 | Bestätigt | H.C. Wainwright | Buy |
| 2020-01-24 | Eingeleitet | SunTrust | Buy |
| 2020-01-23 | Eingeleitet | SunTrust | Buy |
| 2019-11-06 | Eingeleitet | BTIG Research | Buy |
| 2019-06-11 | Eingeleitet | Barclays | Overweight |
| 2019-05-06 | Hochstufung | Mizuho | Underperform → Neutral |
| 2019-05-02 | Hochstufung | Stifel | Sell → Hold |
| 2019-02-01 | Herabstufung | Mizuho | Neutral → Underperform |
| 2018-08-06 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-04-09 | Bestätigt | H.C. Wainwright | Buy |
| 2018-03-21 | Bestätigt | Mizuho | Neutral |
| 2018-02-16 | Herabstufung | Needham | Buy → Hold |
| 2018-01-19 | Eingeleitet | Seaport Global Securities | Buy |
| 2018-01-04 | Bestätigt | Canaccord Genuity | Buy |
| 2018-01-03 | Eingeleitet | Leerink Partners | Mkt Perform |
Alle ansehen
Pacira Biosciences Inc Aktie (PCRX) Neueste Nachrichten
Investors Who Lost Money with Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Should Contact the Shareholders Foundation in Connection with Lawsuit - Newswire :) Press Release Distribution
Can technical indicators confirm Pacira BioSciences Inc.’s reversalJuly 2025 Setups & Safe Capital Allocation Plans - Newser
Volatility clustering patterns for Pacira BioSciences Inc.July 2025 Rallies & AI Powered Market Entry Strategies - Newser
Will Pacira BioSciences Inc. stock recover after recent dropWeekly Trade Analysis & Growth Oriented Trading Recommendations - Newser
Advanced analytics toolkit walkthrough for Pacira BioSciences Inc.2025 Key Lessons & AI Driven Stock Price Forecasts - Newser
Pacira BioSciences Inc. stock trendline breakdownJuly 2025 Catalysts & Safe Investment Capital Preservation Plans - Newser
Is Pacira BioSciences Inc. building a consolidation baseFree Day Trading Signals With High Precision - Newser
Trend analysis for Pacira BioSciences Inc. this weekLong Term Stock Growth Plan Suggestions - Newser
Real time alert setup for Pacira BioSciences Inc. performanceWeekly Setup Summary for Risk Controlled Trades - Newser
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRA) And Encourages Investors to Connect - ACCESS Newswire
Exit strategy if you’re trapped in Pacira BioSciences Inc.Safe Investment Ideas with Growth Upside - Newser
Signal strength of Pacira BioSciences Inc. stock in tech scannersSupport and Resistance Zone Summary Chart - Newser
How Pacira BioSciences Inc. stock performs during market volatilityAI Enhanced Strategy for Portfolio Growth - Newser
Pacira BioSciences Inc (NASDAQ: PCRX) Yet To Convince Analysts? - stocksregister.com
Will a bounce in Pacira BioSciences Inc. offer an exitEntry and Exit Strategy for Swing Traders - Newser
Detecting price anomalies in Pacira BioSciences Inc. with AIFundamental Analysis for Value Stock Selection - Newser
Earnings visualization tools for Pacira BioSciences Inc.Free Short Term Buy Zone Stock Alerts - Newser
Order flow analysis tools used on Pacira BioSciences Inc.Free Real Profit Trade Plan Suggestions - Newser
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Pacira announces layoffs due to efficiencies in Exparel production - MSN
Doma Perpetual's 5.7% Stake in Pacira Biosciences: A Catalyst for Governance Change or Strategic Alignment? - AInvest
Analysts Set Pacira BioSciences, Inc. (NASDAQ:PCRX) Price Target at $25.75 - Defense World
Doma Perpetual Discloses 5.7% Stake in Pacira Biosciences - MarketScreener
Can machine learning forecast Pacira BioSciences Inc. recoveryRisk Balanced Picks for Safer Trading - Newser
Pacira BioSciences, Inc. (NASDAQ:PCRX) Position Lifted by Zurcher Kantonalbank Zurich Cantonalbank - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRA) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q2 2025 Earnings Call Transcript - Insider Monkey
Can Pacira BioSciences Inc. rally from current levelsStrong Buy Opportunity with Volume Support - Newser
Pacira Biosciences Q2 Earnings Call Highlights Growth and Strategy Amid Challenges - AInvest
Pacira BioSciences Reports Q2 2025 Results: EPS of -$0.11 Misses Estimates, Revenue at $181.1 Million Below Expectations - AInvest
Pacira BioSciences Reports Q2 2025 Financial Results: $181.1M Revenue, Net Loss of $4.8M - AInvest
New Product Launches: Will They Boost Pacira BioSciences Inc. Stock in 2025Momentum Entry Alerts with Risk Control - Newser
Pacira Biosciences shares rise 2.09% intraday after Q2 revenue beat expectations. - AInvest
Pacira Biosciences Q2 Non-GAAP Earnings Fall, Revenue Rises; Updates 2025 Sales Forecast - MarketScreener
Pacira BioSciences Posts Strong Q2 Growth, Boosts 2025 Revenue Guidance - AInvest
Pacira BioSciences (PCRX) Bolsters Growth with Strategic Moves - GuruFocus
Pacira BioSciences Inc (PCRX) Q2 2025 Earnings Call Highlights: Strong Growth in EXPAREL Sales ... - Yahoo Finance
Pacira BioSciences Inc (PCRX) Q2 2025 Earnings Call Highlights: Strong Growth in EXPAREL Sales ... By GuruFocus - Investing.com Canada
Pacira BioSciences' Q2 2025: Contradictions Surface on EXPAREL Market Access, Sales, and Margins - AInvest
Pacira BioSciences Q2 2025 Earnings Call Transcript: Key Takeaways - AInvest
Pacira BioSciences Inc (PCRX) Q2 2025 Earnings Call Highlights: - GuruFocus
Pacira BioSciences Q2 2025 Earnings Call Transcript - MarketBeat
Pacira BioSciences Reports Q2 2025 Financial Results - TipRanks
Decoding Pacira BioSciences Inc (PCRX): A Strategic SWOT Insight - GuruFocus
Pacira BioSciences: A Strategic Turnaround in the Opioid-Alternative Sector - AInvest
Pacira Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Pacira BioSciences' Q2 revenue misses estimates - MarketScreener
Pacira BioSciences reports Q2 2025 rev. $181.1mln, net loss $4.8mln. - AInvest
Finanzdaten der Pacira Biosciences Inc-Aktie (PCRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.37%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):